Skip to main content

Table 1 Sensitiser enhancement ratios (SER) for prostate cancer and prostate epithelial cells treated with citrate-AuNP or RALA-AuNP conjugates

From: Formulating RALA/Au nanocomplexes to enhance nanoparticle internalisation efficiency, sensitising prostate tumour models to radiation treatment

  Mean SER DEF @ 2 Gy DEF @ 4 Gy α β
DU145
Radiation 0.15 ± 0.05 0.08 ± 0.007
Citrate-AuNP 0.9 0.9 0.85 − 0.06 ± 0.04 0.04 ± 0.01
RALA-AuNP 1.23 1.22 1.49 0.11 ± 0.07 0.03 ± 0.02
PC-3
Radiation 0.08 ± 0.07 0.032 ± 0.02
Citrate-AuNP 1.14 1.14 1.22 0.147 ± 0.05 0.028 ± 0.02
RALA-AuNP 1.54 1.66 2.04 0.35 ± 0.06 0.006 ± 0.02
PNT2-C2
Radiation 0.199 ± 0.04 0.04 ± 0.01
Citrate-AuNP 1.1 1.17 1.2 0.093 ± 0.091 0.028 ± 0.22
RALA-AuNP 0.96 0.97 1.07 − 0.045 ± 0.15 0.0053 ± 0.0039
  1. SER represents a ratio of the area under the curve for control verses treated cells using a survival fraction baseline of 0.1. DEF provides a ratio of survival fractions for control/AuNP treated at a single fixed dose point e.g., 2 Gy and 4 Gy, the survival fractions of which are extrapolated from the LQ survival curve. Similarly, α and β values have been extrapolated from LQ survival curves